Media coverage about Syndax Pharmaceuticals (NASDAQ:SNDX) has trended somewhat positive on Wednesday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 48.1419127306708 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern’s scoring:
- Syndax Pharmaceuticals Inc (SNDX) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Syndax Pharmaceuticals Inc (SNDX) to Post Q1 2018 Earnings of ($1.20) Per Share, Oppenheimer Forecasts (americanbankingnews.com)
- B. Riley Equities Analysts Lower Earnings Estimates for Syndax Pharmaceuticals Inc (SNDX) (americanbankingnews.com)
- B. Riley Comments on Syndax Pharmaceuticals Inc’s Q1 2019 Earnings (SNDX) (americanbankingnews.com)
Shares of Syndax Pharmaceuticals (NASDAQ SNDX) traded up $1.91 during trading hours on Wednesday, reaching $12.49. 555,605 shares of the company traded hands, compared to its average volume of 375,560. The company has a market cap of $258.05 and a P/E ratio of -4.34. Syndax Pharmaceuticals has a one year low of $7.41 and a one year high of $15.70.
Several analysts have recently issued reports on the stock. Morgan Stanley decreased their target price on shares of Syndax Pharmaceuticals from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Wednesday. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. BidaskClub upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 23rd. Finally, B. Riley restated a “buy” rating and set a $40.00 target price on shares of Syndax Pharmaceuticals in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $24.25.
COPYRIGHT VIOLATION NOTICE: “Syndax Pharmaceuticals (SNDX) Receives Daily News Sentiment Rating of 0.20” was first posted by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/2018/03/14/syndax-pharmaceuticals-sndx-receives-daily-news-sentiment-rating-of-0-20/2029273.html.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.